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Abstract
Expression of fibroblast growth factor 8 (FGF-8) is commonly increased in prostate cancer. Experimental studies have
provided evidence that it plays a role in prostate tumorigenesis and tumor progression. To study how increased FGF-8
affects the prostate, we generated and analyzed transgenic (TG) mice expressing FGF-8b under the probasin pro-
moter that targets expression to prostate epithelium. Prostates of the TGmice showed an increased size and changes
in stromal and epithelialmorphology progressing fromatypia andprostatic intraepithelial neoplasia (mousePIN,mPIN)
lesions to tumors with highly variable phenotype bearing features of adenocarcinoma, carcinosarcoma, and sarcoma.
The development of mPIN lesions was preceded by formation of activated stroma containing increased proportion of
fibroblastic cells, rich vasculature, and inflammation. The association between advancing stromal and epithelial altera-
tions was statistically significant. Microarray analysis and validation with quantitative polymerase chain reaction re-
vealed that expression of osteopontin and connective tissue growth factor was markedly upregulated in TG mouse
prostates compared with wild type prostates. Androgen receptor staining was decreased in transformed epithelium
and in hypercellular stroma but strongly increased in the sarcoma-like lesions. In conclusion, our data demonstrate that
disruption of FGF signaling pathways by increased epithelial production of FGF-8b leads to strongly activated and atypi-
cal stroma,which precedes development ofmPIN lesions and prostate cancerwithmixed features of adenocarcinoma
and sarcoma in the prostates of TG mice. The results suggest that increased FGF-8 in human prostate may also con-
tribute to prostate tumorigenesis by stromal activation.
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Introduction
Fibroblast growth factors (FGFs) are polypeptide growth factors in-
volved in various normal and pathologic processes. Their effects are
mediated by FGF receptors (FGFRs), which are transmembrane tyro-
sine kinase receptors expressed as various splice variants with differential
ligand binding specificities [1]. In prostate, FGFs and their receptors
regulate embryonic development and maintain tissue homeostasis in
the adult by means of directional signaling and reciprocal interactions
between the epithelial and stromal compartments [2]. Elevated levels
of various FGF ligands as well as aberrant expression of FGFRs have
been reported in human prostate cancer and metastases [2,3], and
disruption of FGF pathways in genetically engineered mouse models
has provided evidence for the involvement of aberrant FGF signaling
in prostate tumorigenesis [4–8].
Fibroblast growth factor 8 (FGF-8) is one of the FGF family mem-
bers associated with prostate cancer [9–12] as well as breast [13] and
ovarian cancer [14]. FGF-8 is a mitogenic and transforming growth
factor that has important and widespread roles in embryonic devel-
opment but a strictly restricted expression pattern in adult tissues
[15]. It is expressed and secreted by the epithelium, and it signals
directionally to mesenchyme by binding FGFR3c, FGFR4, FGFR2c,
or FGFR1c [16,17]. There are four isoforms (a, b, e, and f ) of hu-
man FGF-8 [18], of which the b-isoform has been shown to have the
strongest transforming potential in vitro [19].
Several studies have shown up-regulation of FGF-8 expression in
prostate cancer [9–11], and FGF-8 level has been reported to corre-
late with advanced stage and high grade of tumors [12,20] as well
as with decreased patient survival [21]. We reported previously that
FGF-8 is elevated in human premalignant PIN lesions [11], suggest-
ing that this factor is involved in the early steps of prostate tumori-
genesis. This conclusion was supported by the study of Song et al.
[4] who demonstrated that prostate-targeted expression of FGF-8b
induces development of mouse prostatic intraepithelial neoplasia
(mPIN) lesions in transgenic (TG) mice. Besides tumorigenesis, our
previous in vitro and in vivo studies have shown that FGF-8 is also
involved in later stages of tumor progression by increasing tumor
cell invasion and migration as well as angiogenesis and bone metasta-
sis [22–25].
To study the mechanisms by which increased FGF-8 affects the
prostate, we generated a TG mouse model expressing FGF-8b in
prostate epithelium under the probasin (ARR2PB) promoter [26]
in the genetic background of the FVB/N strain. Our data show
that mPIN lesions were frequently observed in TG mice older than
10 months as reported in the corresponding mouse model of Song
et al. [4] generated in the C57BL/6 × DBA2 strain. Our study also
demonstrates that, in addition to mPIN lesions, some old TG indi-
viduals developed prostate cancer with heterogeneous histology,
sharing characteristics of both adenocarcinoma and sarcoma. Impor-
tantly, strong activation of prostate stroma was seen in young 3- to
6-month-old TG mice before and in association with mPIN forma-
tion. Our microarray analyses of the genes differentially expressed in
the TG mouse prostates demonstrated that genes for connective tissue
growth factor (CTGF ) and osteopontin (SPP1) were upregulated in
TG mouse prostates. There were also marked changes in expression
of epithelial and stromal androgen receptor (AR). The results underline
the capacity of FGF-8b to induce prostate cancer and the importance
of stromal activation in FGF-8b–induced prostate tumorigenesis and
tumor progression.
Materials and Methods
Generation of ARR2PB–FGF-8b Transgenic Mouse Lines
A 530-bp-long DNA fragment containing the probasin (ARR2PB)
promoter was digested from pBluescipt II SK+ vector and ligated to a
pcDNA 3.1(−) expression vector in front of human FGF-8b comple-
mentary DNA (cDNA). A 1.8-kb-long DNA fragment containing
the transgene construct (Figure 1A) was then excised from the pcDNA
3.1(−) vector using XhoI and DraIII and ligated to the promotor-
less pGEM7Zf(+) vector for functional testing in vitro. Transgene
construct was purified from agarose gel by using a Quick-Pick electro-
elution Capsule kit (Qiagen, Valencia, CA) and Elutip DEAE columns
(Schlaicher & Shüell, Dassel, Germany) and thereafter microinjected
into the pronuclei of fertilized FVB/N mice oocytes.
Total DNA was extracted from tail or ear biopsies of the offspring,
using DNeasy columns (Qiagen), and the presence of the transgene
was tested by using genotyping polymerase chain reaction (PCR; Fig-
ure W1A) with primers 5′-TACAACTGCCAACTG GGATG-3′ (for-
ward) and 5′-GGCGGGTAGTTGAGGAACTC-3′ (reverse) specific
for the transgene construct. Mice positive for the transgene were used
as founder mice and mated with WT FVB/N mice to establish four
Figure 1. Generation and characterization of FGF-8b transgenic
mice. (A) The transgene construct. (B) Transgene expression was lo-
calized to VP of TGmice by in situ hybridization with FGF-8b–specific
riboprobes (a, b) and by FGF-8b immunostaining (c, d). Expression of
FGF-8b was absent or low in VP samples of WT mice. (C) Represen-
tative pictures of prostate blocks from a 13.5-month-old WT and a
14-month-old FGF-8b TG mouse showing the abnormal, cystic ap-
pearanceof TGmouseprostate. Bl indicatesbladder; LP, lateral pros-
tate; SV, seminal vesicle.
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FGF-8b TG mouse lines (nominated as L2-L5) used for further analy-
sis of the transgene expression and phenotypic features. Animal stud-
ies were approved by the Finnish Animal Ethics committee, and the
institutional policy on animal experimentation fully meets the require-
ments as defined in the National Institutes of Health’s guide on ani-
mal experimentation.
Tissue Preparation
After killing the mice, their body weights were measured, and tissues
of interest for RNA extraction were quickly prepared and frozen in
liquid nitrogen. For histologic preparations, prostate blocks or pros-
tate lobes were removed, weighed, and fixed overnight in 10% neutral-
buffered formalin. Fixed tissues were embedded in paraffin, and 5-μm
sections for standard hematoxylin and eosin staining, immunohistochem-
istry (IHC), and in situ hybridization were prepared.
Androgen Treatment of Prepubertal Mice
For this study, 14-day-old TG (n = 13) and WT (n = 7) male mice
were treated for a 2-week period with subcutaneous daily injections
of testosterone propionate (7 μg/g of body weight; Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) dissolved in maize oil (+1%
ethanol). Control animals were treated with corresponding amounts
of the solvent.
RNA Extraction and Reverse Transcription–PCRs
Total RNA from tissues was extracted using TRIzol reagent accord-
ing to the manufacturer’s instructions (Invitrogen, Life Technologies,
Inc, Carlsbad, CA). After isolation, the RNA was purified and treated
with DNAse in RNeasy columns (Qiagen).
In reverse transcription–PCRs (RT-PCRs), 1 μg of total RNA was
used for cDNA synthesis as described earlier [27]. The sequences
of the primers used in FGF-8b–transgene–specific RT-PCR were 5′-
GGACACCTTTGGAAGCAGAG-3′ (forward) and 5′-CAACA-
GATGGCTGGCAACTA-3′ (reverse) and those in β-actin RT-PCR
were 5′-TTGTAACCAACTG GGACGATATGG-3′ (forward) and R
5′-GATCTTGATCTTCATGGTGCTAGG-3′ (reverse).
In quantitative RT-PCRs (qRT-PCRs), cDNA were amplified using
Quantitect SYBR green reagent (Qiagen) for two-step RT-PCR with
amplification conditions recommended by the manufacturer’s hand-
book. Reactions were performed in triplicate in DNA Engine Opticon
(MJ Research, Inc, Waltham, MA). Primer sequences for FGF-8b
qRT-PCR were 5′-CCAAGCCCAGGTAACTGTTCA-3′ (forward)
and 5′-AGGACCTGCACGTGCTTC-3′ (reverse) and those for β-
actin qRT-PCR were 5′-CGTGGGCCGCCCTAGGCACCA-3′
(forward) and 5′-TGGCCTTAGGGTTCAGGGGG-3′ (reverse). Rela-
tive expression levels were calculated by the 2−ΔΔCTmethod [28] using
β-actin as a reference gene.
FGF-8b In Situ Hybridization
Human FGF-8b cDNA derived from pcDNA 3.1 (−) expression
vector was used as a template in a PCR to amplify the FGF-8b sequence
for riboprobe synthesis. Sequences of the PCR primers used containing
the binding sites of T7 and T3 RNA polymerases (indicated with bold
letters) were 5′-CAGAGATGCATAATACGACTCACTATAGGGA-
GACCAA GCCCAGGTAACTGTTCAGTCC-3′ (forward) and
5 ′ -CCAAGCCTTCATTAACCCTCACTAAAGGGAGA-
TTCCCCTTCTTGTTCATGCAGATGT-3′ (reverse). Purification
of the PCR product and synthesis of the digoxigenin-labeled riboprobes,
as well as pretreatment of sample slides, the hybridization procedure,
and the subsequent treatments were carried out as described previously
[29]. Hybridization was performed overnight at 55°C with probe
concentrations of 100 ng/ml.
Histologic Classification
Histologic analysis of prostates (n = 72 TG mice from lines L2, L4,
and L5 and n = 43 littermate WTmice) using the Bar Harbor classi-
fication system [30] was performed in a blinded manner (T.E.). The
results of the analysis were confirmed by a clinical pathologist (P.K.).
Immunohistochemical Stainings
Paraffin-embedded sections were used for immunostaining, with the
exception of CD68 staining, which was performed using frozen sec-
tions. Antigen retrieval was performed with 10 mM citrate buffer,
pH 6, in a microwave oven (FGF-8b, CD3, and CD45R/B220 stain-
ings), with citric acid buffer, pH 6, in a pressure cooker (AR staining),
with proteinase K (cytokeratin staining) or Ficin (Zymed, San Francisco,
CA) at 37°C (laminin staining). Antibodies used were anti–FGF-8b
(AF-423-NA; R&D Systems, Abingdon, UK), anti-AR (SC-816;
Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD3 (ab5690;
Abcam,Cambridge,UK), anti-CD45R/B220 (550286; BDPharmingen,
San Diego, CA), anti-CD68 (MCA1957; AbD Serotec, Kidlington,
UK), anti-SMA (MS-113-P; NeoMarkers, Fremont, CA), antilaminin
(L9393; Sigma-Aldrich, St Louis, MO), anticytokeratins (Z0622;
DAKO, Glostrup, Denmark), and anti-SPP1 (AF808; R&D Sys-
tems). Biotinylated secondary antibodies, avidin-biotinylated peroxi-
dase complex (Vectastain ABC kit, PK-4000; Vector, Inc, Burlingame,
Table 1. Genes Analyzed and Primers Used in the Probe Library qRT-PCR.
Gene (Symbol) Primers 5′-3′
Apolipoprotein D (APOD) F: ACGGAAACATCGAAGTGCTAA, R: TGGCTTCACCTTTACTTGG
Clusterin (CLU ) F: TGCTGATCTGGGACAATGG, R: CTCCCTTGAGTGGACAGTTCTT
Connective tissue growth factor (CTGF ) F: TGACCTGGAGGAAAACATTAAGA, R: AGCCCTGTATGTCTTCACACTG
Early growth response (EGR1) F: CCTATGAGCACCTGACCACA, R: TCGTTTGGCTGGGATAACTC
Forkhead box Q1 (FOXQ1) F: CAGGTCGGTGCCTGAGAC, R: CGCTTATGCTATCGGTCTGG
Lipocalin (LCN2) F: CCATCTATGAGCTACAAGAGAACAAT, R: TCTGATCCAGTAGCGACAGC
Ribosomal protein L19 (L19) F: TCGTTGCCGGAAAAACAC, R: CCGAGCATTGGCAGTACC
Secreted phosphoprotein, osteopontin (SPP1, OPN ) F: CCCGGTGAAAGTGACTGATT, R: TTCTTCAGAGGACACAGCATTC
Seminal vesicle protein secretion 2 (SVS2) F: ACAGTCAGCTGTGTTTGTACAATATG, R: GCCTTTCTGACCAAGCATAAA
Small proline-rich protein 1A (SPRR1A) F: CCTGAAGACCTGATCACCAGA, R: AGGCAATGGGACTCATAAGC
Small proline-rich protein 2A (SPRR2A) F: CTGCTCCGGAGAACCTGAT, R: ACAAGGCTCAGGGCACTTC
Sonic hedgehog (SHH ) F: TCCACTGTTCTGTGAAAGCAG, R: GGGACGTAAGTCCTTCACCA
Transglutaminase 4 (TGM4, EAPA1) F: TGCAGAGAGAGGTAGCAGGAC, R: TCTCTCCACATTCACAGCGTA
Unknown gene (GI 38086179) F: CCTGGAGGACAGACAGCATC, R: TGGCAGGAATGTGTACAGATAGA
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CA) and 3,3′-diaminobenzidine (DAB substrate kit SK-4100; Vec-
tor, Inc) were used for visualization, and Mayer hematoxylin was used
for counterstaining.
Microarray Analysis
Illumina Sentrix Mouse-6 oligomicroarray BeadChips (Illumina, San
Diego, CA) containing 47,769 oligos were used for studying gene ex-
pression levels in the ventral prostates (VPs) of 3-month-old TG and
WTmice (n = 3 per group). Quality control of RNA and the microarray
hybridization protocol were performed at the Finnish DNA microarray
center (Turku, Finland) according to the manufacturer’s protocol.
Gene Spring 7.2 software (Agilent Technologies, Santa Clara, CA)
was used for analysis of the microarray data and Ingenuity Pathways
analysis software (IPA, Ingenuity Systems; http://www.ingenuity.com)
for mining the data and constructing functional regulatory networks.
Microarray data verification concerning 13 selected genes (Table 1) in
the VPs of 3-month-old TG andWTmice (n = 5 per group) was carried
out bymeans of a probe-based qRT-PCRmethod (ProbeLibrary; Roche
Diagnostics GmbH, Roche Applied Science, Basel, Switzerland) at the
Turku Center of Biotechnology. An online assay design program (Probe
Finder; http://www.universalprobelibrary.com) was used to design suit-
able primer pairs (Table 1). L19 was used as a housekeeping gene for
normalization of the expression levels. The expression of SPP1 and
CTGF were further studied, using the same primers, by means of the
SYBR green–based qRT-PCR method as described earlier.
Scoring the Histologic Changes and
Immunohistochemical Stainings
For statistical analysis studying the association between the epithelial
and stromal changes and between the epithelial changes and inflamma-
tion, TGmice (aged 9-20months, n = 49) were divided into four groups
according to the most advanced histologic change in their prostate
epithelium (normal, hypercellular, mPIN, and carcinoma). Age of
mice did not differ between the groups (analysis of variance, P = .093).
A numeric score (from 1 to 4) was given to each sample according to
the most advanced histologic change present in the prostate stroma as
follows: 1, normal stroma; 2, hypercellular stroma; 3, atypical stroma;
and 4,malignant stroma. Evaluation of the degree of prostatic inflamma-
tion (scores from 0 to 3) was based on themean number of inflammatory
cell aggregates in the prostate stroma in ×40 microscopic field as follows:
0, no signs of inflammation; 1, mild inflammation presented by one to
three aggregates of inflammatory cells; 2, moderate inflammation with
four to seven aggregates of inflammatory cells; and 3, pronounced in-
flammation with more than seven large aggregates of inflammatory cells.
Staining grade of AR was defined from sections stained by AR IHC
by estimating the percentage of positively stained nuclei in the VP epi-
thelium and stroma (WT, n = 9, aged 3-16 months; TG, n = 13, aged
3-18.5 months). In cases of normal histology or stromal proliferation,
the mean percentage of AR-positive cells was defined by evaluating at
least five representative microscopic fields at ×400 magnification. For
mPIN lesions, the proportion of AR-positive cells was estimated for
each mPIN containing acinus, and the mean proportion per acinus
was calculated. For carcinoma, stromal atypia, and sarcoma, total areas
containing the respective changes were evaluated.
Statistical Analysis
Statistical analyses were carried out using SPSS 11.0 for Windows
(SPSS, Inc, Chicago, IL). The normality of distributions was tested
by using the Shapiro-Wilk W test. Differences between groups were
thereafter tested by the two-sample t-test, the Mann-Whitney U test,
or the analysis of variance. In analysis containing multiple comparisons,
Bonferroni corrections for P values were applied. Logistic regression
analyses (LRAs) were applied to studywhich histologic changes (inserted
as binary categorical variables: present or absent) could predict the
presence of mPIN lesions in TGmouse prostates. The predictive ability
of each factor was studied separately and adjusted for age. Values of P <
.05 were considered statistically significant.
Results
Generation and Analysis of FGF-8b Transgenic Mice
Four FGF-8b TG mouse lines (L2-L5) were generated, and their
analysis by RT-PCR showed that FGF-8b was expressed in the ventral,
dorsolateral, and anterior prostate (VP, DLP, and AP), the ductus defe-
rens, the urethra, the epididymides, and the seminal vesicles of 3-month-
old TG animals with the highest expression in VP (Figure W1B). No
significant expression was detected in other tissues studied. According
to the qRT-PCR data, FGF-8b messenger RNA (mRNA) levels in the
VPs of all four TG mouse lines were hundred to several thousand times
higher than in the WTmice, and the expression levels remained high in
the VPs of old (12- to 16-month-old) TG mice (Figure W1C). By way
of in situ hybridization and FGF-8 IHC, transgene expression was de-
tected in prostate epithelia (Figure 1B) of young and old TG mice. In
line with the qPCR data, the staining was strongest in the VP.
Figure 2. FGF-8b transgenic mice develop advancing histologic changes in prostate epithelium and stroma. (A) Representative pictures of
histologic changes in hematoxylin and eosin–stained sections (a, WT; b-i, TG). Normal VP histology, WT, 16-month-old (a); stromal hyper-
cellularity and increased vasculature in VP, TG, 4-month-old (b); hypercellularity of VP epithelium, TG, 6-month-old (c); mucinous metaplasia
in VP, TG, 13-month-old (d); advancedmPIN lesion in VP, TG, 16-month-old (e); adenocarcinoma in VP, TG, 13-month-old (f); atypical stromal
hypercellularity showing phyllodes growth pattern and inflammation, TG, 14.5-month-old (g); sarcoma in VP, TG, 13-month-old (h); and
carcinosarcoma in VP, TG, 18.5-month-old (i). Images were taken at ×100 to ×200 magnification, and inserts were taken at ×400 magni-
fication. Scale bars, 100 μm. (B) Frequencies (%) of histologic changes in the oldest age group (12-21 months old) of TG and WT mice.
Carcinosarcomas were included in the sarcoma group. (C) Immunohistochemical staining of FGF-8b in neoplastic lesions of FGF-8b TG
mouse prostates. VP glands with normal-appearing histology located next to a big carcinosarcoma lesion in a TG prostate (a), mPIN lesions
in the VP of a TGmouse (b), adenocarcinoma in the VP of a TGmouse (c), and carcinosarcoma in the same prostate as the normal-appearing
glands in subpanel a (d). Images were taken at ×200 magnification. Scale bars, 100 μm. (D) Association between epithelial and stromal
changes in TG prostates. Mean scores of stromal phenotypes in TG mouse groups (9-20 months old) defined by the histologic status of
prostatic epithelium. Numeric values (1-4) for stromal phenotype were given as indicated in the Materials and Methods section. The
bars show themeans±SEs. Statistical significancewas assessedwith theMann-WhitneyU tests, and Bonferroni correctionswere applied.
***P < .001, *P < .05.
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Epithelial Overexpression of FGF-8b Induces Morphologic
Changes in the Prostate and Other Urogenital Organs
Altogether, 133 TGmice at ages varying from 2.5 to 20months were
macroscopically examined and compared with WT littermates at au-
topsy. The gross phenotype or body weights of the TG animals did
not differ from those of their WT littermates (data not shown). The
weights of the VP and the DLP were higher in TG mice, the difference
being statistically significant in mice older than 6 months (VP) and
8 months (DLP), respectively (Figure W2). The VPs of TG mice were
not only increased in size but also presented swellings, hemorrhagic
cysts, and tumors, especially in TG mice older than 10 months.
In some TG animals, morphologic changes, such as increased size,
swellings, or tumor-like morphology, were also observed in epididymi-
des and seminal vesicles (data not shown). Accordingly, male infertility
with a varying frequency (33%-75%) was observed in three TG mouse
lines. Studies on the mechanisms underlying the infertility/subfertility
are ongoing.
FGF-8b TG Mice Develop Stromal Hypercellularity, mPIN,
and Neoplastic Lesions with Mixed Histology of
Adenocarcinoma and Sarcoma
Histologic analysis of TG mice (L2, L4, and L5) revealed progressive
changes in prostate epithelium and stroma, with frequencies and se-
verity increasing on aging (Figure 2, A and B, and Table W1). Most
changes (75%) were located in the VP, whereas some were also found
in DLP and less frequently in AP.
The most obvious change in the VPs of young (3- to 6-month-old)
TG mice compared with WTmice was the mild or moderate stromal
hypercellularity (frequency, 56%) often associated with increased vascu-
lature (Figure 2A, b). VPs of young TG mice also frequently contained
epithelial changes such as hypercellularity, dilation of acini, and mucin-
ous metaplasia (Figure 2A, c and d ). Epithelial hyperplasia with atypia
characterized by cells with enlarged hyperchromatic nuclei became
more common in older (>6-month-old) TG mice. Focal or multifocal
mPIN lesions (Figure 2A, e) were first observed in 7- to 11-month-old
TG mice (19%) and in almost half (47%) of the older TG mice (>12-
month-old). Besides mPIN lesions, malignant changes classified as
adenocarcinoma (Figure 2A, f ) were found in VPs of some old TG
individuals (8%). Atypical changes in the stroma, characterized by
big abnormal cells (Figure 2A, g), with enlarged nuclei and numerous
prominent nucleoli, were first observed in 10-month-old TG mice and
became more common in mice older than 12 months (32%). In some
cases, the expanded atypical stroma presented a focal phyllodes-type
growth pattern (Figure 2A, g). On the basis of the destructive growth
pattern, prominent mitotic activity, markedly increased cellularity,
and marked nuclear atypia, stromal atypias were classified as sarcomas
(Figure 2A, h and i) in six animals. In five of these, both adenocarci-
noma and sarcoma-like tumor areas were found in the same prostate,
and in three of these, the lesions were classified as carcinosarcomas
because the adenocarcinoma and sarcoma-like areas colocalized
(Figure 2A, i).
Expression of FGF-8b in the neoplastic lesions was studied by FGF-
8b immunostaining (Figure 2C ). In all the prostates with neoplastic
lesions, the glandular epithelium with normal-appearing histology
showed positive staining for FGF-8b in the epithelial cell cytoplasm
and/or in the luminal secretion (Figure 2C , a). Most mPIN lesions
showed FGF-8b immunoreactivity at least in some places (Figure 2C ,
b). Most tumor cells in adenocarcinoma lesions also stained positively
for FGF-8b (Figure 2C , c). Sarcomatous areas did not show any stain-
ing, and tumor cells in carcinosarcoma were not stained either (Fig-
ure 2C , d ).
mPIN Lesions and Malignant Changes in FGF-8b TG Prostates
Are Associated with Stromal Changes and Inflammation
Stromal and epithelial changes and aberrances often coexisted in the
same prostates. The mean score of stromal phenotype, increasing with
Figure 3. Aggregates of inflammatory cells in TG prostates are
associated with epithelial changes. (A) Detection of inflammatory
cell types by IHC staining. B-cell–specific CD45R IHC in a TG VP
presenting pronounced inflammation in the prostatic stroma (a).
T-cell–specific CD3 IHC in the same region as in subpanel a (b).
Macrophage-specific CD68 IHC staining in WT mouse VP (c) and in
TG mouse VP (d). Magnification, ×200. Scale bars, 100 μm. (B) De-
gree of inflammation in TGmouse groups (9-20 months old) defined
by the histologic status of prostatic epithelium (groups as in Fig-
ure 2C ). Evaluation and scoring (scores 0-3); the degree of inflamma-
tion was performed as described in the Materials and Methods
section. The bars show the means ± SEs. Statistical significance
was assessed with the Mann-Whitney U tests, and Bonferroni cor-
rections were applied. **P < .01, *P < .05.
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the severity of stromal changes, was found to be significantly higher
(Mann-Whitney U test) in TG prostates containing mPIN lesions or
adenocarcinoma compared with TG prostates with normal epithelium
(Figure 2D).
Inflammation was also a common finding (incidence, >50%) in
prostates of 7- to 21-month-old TG mice (Table W1). Immunohisto-
chemical stainings for the expression of CD3, CD45R/B220, and CD-
68 demonstrated that the aggregates of inflammatory cells contained T
cells, B cells, and numerous macrophages (Figure 3A). Aggregates of
inflammatory cells were often found in the prostatic stroma adjacent
to mPIN lesions usually scattered in the prostatic stroma (Figures 2A,
b and g, and 3A), but in some cases of pronounced inflammation (score
2-3), they were also found in the glandular lumina. The degree of
inflammation was found to be significantly higher (Mann-Whitney U
test) in TG prostates containing mPIN or adenocarcinoma than in
TG prostates presenting less advanced changes or normal epithelium
(Figure 3B).
Stromal hyperplasia, inflammation, mucinous metaplasia, and epi-
thelial hyperplasia were found to be factors with significant predictive
ability for mPIN lesions by LRAs, and the predictive ability of these
factors remained significant when age-adjusted analyses were performed
(Table W2). Age was also found to be significantly associated with
mPIN lesions by LRA (P = .0051; odds ratio, 1.20; 95% confidence
interval, 1.06-1.37).
FGF-8b TG Prostates Present Epithelial Dedifferentiation
and Collagen-Rich Stroma
In most cases, epithelial cells in mPIN lesions of TG mice showed
positive staining for cytokeratins. However, areas of decreased staining
for cytokeratins were found in some mPIN lesions and especially in
adenocarcinoma and carcinosarcoma lesions indicating dedifferentia-
tion of transformed epithelial cells (Figure 4A). Atypical stromal cells
and sarcoma-like lesions in TG prostates were negative for cytokeratins.
Laminin staining, visualizing the basal lamina, was often more pro-
nounced in TG prostates presenting stromal hypercellularity than in
WT prostates, and a thickened laminin-positive layer was observed
around the glands (Figure 4A). In contrast, a discontinuous layer of
laminin-positive cells around the epithelial structures was frequently
observed in TG prostates containing mPIN, carcinoma, or sarcoma-
like lesions. Disruption of laminin-positive layer was most obvious in
prostates containing malignant changes.
Immunostaining for smooth muscle α-actin (SMA) showed that in
histologically normal WT and TG prostates, most stromal cells were
positive for SMA and formed a circular layer surrounding the acini
(Figure 4A). In contrast, in TG prostates with stromal hypercellularity,
the periacinar stromal cells were negative for SMA. Similarly, the atypi-
cal stroma surrounding mPIN lesions and adenocarcinomas was
SMA-negative, and sarcomatoid foci were almost completely negative
for SMA.
Masson trichrome staining was performed to further characterize the
hypercellular stroma in TG prostates (Figure 4A). Prostates from young
and old TGmice containing stromal proliferation and relatively normal
epithelium or early PIN lesions showed increased blue green staining
around the glandular structures, indicating the presence of increased
amount of collagen fibers, which are mainly produced by fibroblastic
cells. Atypical stroma around more advanced mPIN lesions and adeno-
carcinoma and in sarcoma-like foci showed mixed, disorganized stain-
ing patterns of purple and blue green.
FGF-8b Expression Induces Formation of Collagen-Rich
Periacinar Stroma in Prepubertal TG Mice
To further study the effect of FGF-8b, expression of the androgen-
driven ARR2PB-FGF-8b transgene was induced by treating prepubertal
(14-day-old) mice with testosterone for a 2-week period. The induction
of transgene expression by the treatment in TG prostates was verified
by FGF-8 IHC (data not shown). The epithelial morphology in the
prostates of androgen-treated TG animals did not differ from that of
WTmice, but a slightly thickened layer of periacinar stroma was ob-
served in VPs of TGmice. This newly formed stroma stained blue green
in Masson trichrome staining (Figure 4B), indicating that it was rich in
collagen, in a manner similar to the hypercellular stroma seen in the
prostates of adult (3- to 6-month-old) TG mice.
Expression of SPP1 and CTGF Is Upregulated in FGF-8b
TG Mouse Prostates
To study potential differences in gene expression between TG and
WTmice, VP samples of 3-month-old TG andWTmice were analyzed
using Illumina Sentrix Mouse-6 oligomicroarray BeadChips. On the
basis of the results of the microarray analysis (data not shown), 13 genes
(Table 1) that showed differential expression between TG andWTmice
were selected for validation by qRT-PCR. The results confirmed that
the expression levels of SPP1, CTGF, apolipoprotein D (APOD), and
forkhead box 1 (FOXQ1) were significantly upregulated in young TG
mice compared with those in WTmice (t and Mann-Whitney U tests,
P = .028, P = .004, P = .009, and P = .047, respectively). A tendency
toward higher expression levels of early growth response 1 (EGR1) in
3-month-old TG mice was also verified (t test, P = .067). For SPP1 and
CTGF, a significantly upregulated expression was also verified in older
(12- and 15-month-old) TG mice (Figure 5A). Immunohistochemical
stainings demonstrated that in TG prostates with stromal proliferation,
stromal cells, especially adjacent to the epithelium, were positive for
SPP1 (Figure 5B). In mPIN and adenocarcinoma lesions, some of
the epithelial cells also showed positive immunostaining for SPP1.
FGF-8 TG Mouse Prostates Display Altered AR Expression
Immunohistochemical staining of AR was carefully evaluated by es-
timating the occurrence of AR-positive cells in prostate epithelium and
stroma of TG andWTmice. Similar toWTmice, almost all nuclei were
positive for AR in the normal epithelium of young TG mice (Figure 6,
A, a and b, and B). In mPIN foci and adenocarcinoma lesions, the stain-
ing pattern of AR was more heterogeneous, and in many cases, the per-
centage of AR-positive cells was clearly decreased (Figure 6, A, c and d
and B). In normal or hyperplastic stroma of TG mice, the frequency of
AR-positive cells was also lower than that in the stroma of WTmice
(Figure 6, A, a and c, and B). In contrast to this, the frequency of AR-
positive cells was high in stromal areas containing atypical hyperplasia
and especially in sarcoma-like foci (Figure 6, A, e and f, and B).
Discussion
Increased expression of FGF-8 has been reported in human premalig-
nant PIN lesions and prostate cancer [9–11], and it has been shown to
correlate with advanced stage and grade of the prostate malignancy
[12,20]. To study the mechanisms by which FGF-8b affects the pros-
tate, we generated a transgenic mouse model with a prostate targeted
overexpression of FGF-8b, which was, based on previous results of Song
et al. [4], expected to lead to mPIN lesion formation. Our results dem-
onstrate that FGF-8b expression induced development ofmPIN lesions,
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which was preceded by and associated with strong stromal stimulation.
Our study also shows for the first time that, except for the development
of mPIN lesions [4], prolonged overexpression of FGF-8b in mouse
prostate leads to prostate cancer withmixed histologic features of adeno-
carcinoma and sarcoma.
Our results suggest that stromal activation is an early event preceding
and possibly facilitating the development of mPIN lesions in the pros-
tates of FGF-8b TG mice. Signs of stromal stimulation and accumula-
tion of collagen-rich stroma were observed around normal prostatic
acini of young adult TGmice (3- to 6-month-old). Stromal proliferation
Figure 4. Altered staining for cytokeratins, laminin, and smooth muscle actin in FGF-8b TG mouse prostates. (A) Immunohistochemical
staining for cytokeratins (CKs), laminin, smooth muscle α-actin (SMA), and Masson trichrome staining. VP samples from WT mice (left
panel), TG mice with mPIN and stromal hypercellularity (middle panel), and a TG mouse with carcinosarcoma (right panel). Magnification,
×200. Scale bar, 100 μm. (B) Masson trichrome staining of VP sections of prepubertal (28-day-old) WT and TG mice. A thicker layer of blue
green–stained stroma (arrow) was detected around the acini of TG mice administrated 14 days with testosterone-propionate (Te) than
around those of the WTmice with the corresponding treatment (lower panel). Control mice (upper panel) were treated in the similar manner
without testosterone. Magnification, ×200. Inserts, ×400. Scale bars, 100 μm.
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could also be induced by a short (2-week) testosterone treatment
of prepubertal (14-day-old) TG mice, which further suggests that it
was an increased expression of the androgen-driven FGF-8b transgene
that led to stromal stimulation before the appearance of epithelial
changes. Primary stromal responses could be expected because the
FGFR c-isoforms binding the epithelium-secreted FGF-8b are known
to be more abundant in the stromal than in the epithelial compartment
[2]. Our results differ from those of the earlier FGF-8 TG study [4],
which reported development of histologic changes primarily in the pros-
tate epithelium, whereas the stromal changes appeared late, generally in
mice older than 17 months.
The expanded prostate stroma of TG mice showed increased histo-
chemical staining for collagen fibers, whereas immunostaining for SMA
was gradually lost on tumorigenesis, suggesting that the hypercellular
changes were mainly formed by fibroblastic cells. Inflammation and
increased vasculature were also seen in hypercellular prostatic stroma
of our TG mice. Advanced stromal alterations and inflammation were
found to be associated with epithelial changes in the prostates of our
FGF-8b TG mice. Accordingly, stromal hypercellularity and inflamma-
tion were found to be predictive for the presence of mPIN lesions.
These results support the idea that stromal activation facilitated the de-
velopment of mPIN lesions and carcinoma in TG mouse prostates.
Stromal hypercellularity and inflammation observed in our TG mice
resemble characteristics of the “reactive stroma” found in association
with human PIN lesions and prostate cancer [31]. Previous studies with
xenograft models in which LNCaP prostate cancer cells were grown
together with human prostate stromal cells in nude mice have demon-
strated that reactive stroma can promote prostate tumorigenesis for ex-
ample by inducing angiogenesis [32]. Reactive stroma has also been
shown to be a marker for human cancer progression [33].
In the microarray analysis of the gene expression patterns in FGF-8b
TG and WTmouse VPs, SPP1 and CTGF were identified as highly
upregulated genes in TG mice. The qRT-PCR validation analyses
confirmed the results and showed that these genes were strongly up-
regulated in the prostates of both young and old FGF-8b TG mice.
Previous studies have associated CTGF and SPP1 with the develop-
ment of activated stroma and inflammation [34,35], which suggests
that these genes play an important role in the prostate alterations of
our FGF-8b TG mice. Increased expression of SPP1 has been linked
to prostate tumorigenesis and metastasis in several studies [36,37], and
there is evidence, that in experimental prostate cancer models, its ex-
pression is induced by FGF-8 [25,38] and by activation of FGFR1
[39]. In contrast to previous studies that have reported an increased
expression of SPP1 by the transformed epithelium [38], our present
data suggest that, in the FGF-8b TGmouse prostates, SPP1 is primarily
produced by the hypercellular stroma and only to a limited extent by
transformed epithelial cells. Stromal origin of SPP1 is in line with the
results from our previous study [25], which showed that expression
of SPP1 was upregulated in FGF-8b–overexpressing orthotopic PC-3
tumors but not in in vitro cultures of FGF-8b–transfected PC-3 cells. It
is possible that stromal SPP1 functions as an important preneoplastic
cell growth–promoting factor as suggested by Pazolli et al. [40]. Up-
regulation of another gene, APOD, observed in TG prostates in our
microarray study could also be linked to increased SPP1 [41]. APOD
has been shown to be a marker of high-grade PIN and prostate cancer
in humans [42] but its function in the prostate is unknown. Increased
expression of CTGF in FGF-8 TG prostates is also in line with the phe-
notype of activated stroma because CTGF has been shown to be a me-
diator of TGF-β induced formation of reactive stroma, angiogenesis
Figure 5. Up-regulation of CTGF and SPP1 expression in TG mouse
prostates. (A) qRT-PCR analysis of relative expression levels of CTGF
and SPP1 mRNA in FGF-8b–TG and WT mouse VPs in three age
groups. The lowest expression value among WT mouse samples
was used as a reference and set to 1. Statistical significance was as-
sessed with the t test (CTGF) or the Mann-Whitney U tests (SPP1).
**P < .01, *P < .05. (B) Immunohistochemical staining of SPP1 in
WT mouse VP (a), in TG mouse VP with stromal proliferation (b), in
TGmouse VPwith mPIN (c), and in TGmouse prostate with carcino-
sarcoma (d).Magnification,×200. Inserts,×400. Scale bars, 100μm.
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and tumor growth [35]. Our previous studies have demonstrated that
FGF-8 increases angiogenesis [22,24], and rich vasculature was also seen
in the hypercellular stroma of TG mice. Up-regulation of CTGF could
be one of the mechanisms mediating this effect of FGF-8.
The malignancies in the prostate of old FGF-8b TG mice displayed
a highly variable morphology including adenocarcinoma, sarcoma, and
carcinosarcoma-like lesions. It is intriguing that the mixed neoplastic
lesions in the FGF-8b TG mouse prostates showed marked similarities
to those observed in the FGFR1 TG mice [8], in which FGF pathways
had been disrupted by inducing FGFR1 activation in the prostate epi-
thelium. This suggests that FGFR1 is involved in the induction of
malignant development in the FGF-8b TG prostates and that the
mechanisms underlying the development of mixed prostate tumor
phenotype in two mouse models could also bear similarities. How-
ever, activation of other FGF-8b binding FGFRs (FGFR2c, -3c, and
-4) expressed in prostate [2] is also possible in the FGF-8b TG mice.
Induction of FGFR2c expression has been reported in transformed
prostate epithelium [43,44], but previous studies have shown that
the transgenic mice expressing activated FGFR2c in epithelium do
not develop hyperplasias or dysplasias like those with the activated
FGFR1c [6]. There is also evidence that epithelial FGFR2 is required
to maintain normal tissue homeostasis in prostate and could have a
role opposite that of FGFR1 in prostate tumorigenesis [45]. There
is less information on the role of FGFR2c in prostate stroma, but in
Figure 6. FGF-8b TGmouse prostates present altered AR staining. (A) IHC staining of AR in VP of aWTmouse (a), in TG prostate with stromal
hypercellularity and inflammation (b), in an mPIN focus of a TG mouse (c), in adenocarcinoma (d), in sarcoma (e), and in carcinosarcoma (f).
Magnification: all, ×100; d, ×200. Inserts, ×200. Scale bars, 100 μm. (B) Staining grades in AR IHC in VP epithelium (upper graph) and
stroma (lower graph) of WT and TG mice with normal and altered histology. Grades were evaluated as proportion of AR-positive cells in
the VP areas with respective changes as indicated in the Materials and Methods section.
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FGF-8b–expressing TG prostates, it might contribute to stromal acti-
vation. FGFR3 does not seem to have a central role in the pathogenesis
of prostate cancer [44,46], whereas increased epithelial expression and a
polymorphism of the FGFR4 gene have been associated with human
prostate cancer progression [44,47]. Taken together, altered function
of different FGFRs in epithelium and stroma can contribute to the ob-
served prostate phenotypes in FGF-8b TG mice in a complex way.
The heterogeneous tumor phenotype in the FGF-8b TG prostates
raises the question of which cell type(s), particularly in the case of
sarcoma-like foci, have given origin to tumor cells. In the FGFR1
TG model formation of “sarcomatoid carcinomas” was suggested to
result from an epithelial-to-mesenchymal transition (EMT) and sub-
sequent invasion of epithelium-derived tumor cells to stroma [8,48].
We have previously found that FGF-8b induces fibroblastic phenotype
and anchorage independent growth in S115 breast cancer cells [22],
which supports a possibility of EMT in appearance of malignant cells
in prostatic stroma of our FGF-8b TGmice. In addition, stromal tumor
cells in our FGF-8b TG mice expressed AR, which also speaks for the
possibility of transdifferentiation of epithelium-derived tumor cells to
sarcoma-like phenotype. The decreased cytokeratin staining in the
transformed epithelial cells of adenocarcinoma and carcinosarcoma
lesions could also be interpreted as a sign of EMT. Nevertheless, positive
immunostaining of FGF-8b in the adenocarcinomas and negative
staining in the sarcomas and carcinosarcomas could be interpreted as
a sign of different origin of these lesions, which suggests that the stromal
malignancies are formed by secondary mechanisms. With the pres-
ent data, it is, however, impossible to determine the cellular origin of
sarcoma-like lesions in the FGF-8b TG mice.
The expression of AR was decreased in normal and hypercellular
stroma as well as in dysplastic andmalignant epithelium of TG prostates.
The decrease of stromal AR is in line with our other results indicating
increased proportion of fibroblastic and decreased smooth muscle cells
in TG prostates because AR is known to be expressed by smooth muscle
cells in the normal prostate stroma, whereas most fibroblastic cells are
negative for AR [49]. The decrease in epithelial AR expression could be
associated with epithelial dedifferentiation. Stromal ARs are considered
to regulate normal differentiation and function of prostatic epithelium
and to repress epithelial proliferation [50]. Accordingly, Wikstrom et al.
[51] recently reported that lowered AR in prostate stroma is related
to poor prognosis in prostate cancer patients. Therefore, decrease of
AR in the hypercellular but nontransformed stroma of our TG mice
could be one of the mechanisms behind increased epithelial prolifera-
tion and dedifferentiation.
Opposite the normal and hypercellular TG prostate, stroma AR-
positive cells were abundant in atypical stroma and especially in the
areas of carcinosarcoma and sarcoma-like lesions. These AR-positive
cells were SMA-negative, which suggests fibroblastic or epithelial ori-
gin. It is possible, as discussed earlier, that these AR-positive cells
are epithelium-derived stroma-invaded cells as suggested for FGFR1
TG prostates [8]. Another possibility is that AR expression is upregu-
lated in malignant stromal cells of TG prostates. Some of the lesions in
FGF-8b TG prostates resemble “stromal tumors of uncertain malig-
nant potential” (STUMPs), which are rare stromal lesions in human
prostate [52]. Most of the human STUMPs are benign, but a subset
can develop to sarcomas. The phyllodes growth pattern seen in a subset
of human STUMPs and sarcomas was also seen in stromal atypias of
FGF-8b TG mice. Interestingly, strong AR expression has been re-
ported for human STUMPs and sarcomas [53]. Taken together, altera-
tions in the AR expression in FGF-8b TGmouse prostates suggest that
autocrine/paracrine FGF signaling can directly or indirectly modulate
AR levels as has been shown for other growth factor pathways [54]. In
line with this, increased stromal FGF-10 has been shown to enhance
Figure 7. A proposedmodel for FGF-8 action in prostate. (A) Increased levels of FGF-8b are secreted by the epithelial cells. It affects both the
epithelium and the stroma (autocrine and paracrine effects, pink arrows). (B) The affected stroma presents features of reactive stroma, such
as increased amount of fibroblasts, inflammation, and angiogenesis. Altered stroma secretes connective tissue growth factor (CTGF), SPP1,
and other (unidentified) factors that can affect the epithelium. The disturbed cross talk (indicated by green arrows) between stromal and
epithelial compartment together with increased amounts of FGF-8b induce proliferation and dedifferentiation of the epithelium, leading to
the development of preneoplastic mPIN lesions. (C) Prolonged FGF-8b exposure and disturbed epithelial-to-stromal cross talk induces
the epithelium and the stroma to develop atypical andmalignant changes. AR-positive nuclei are presented by dark gray; AR-negative nuclei,
light gray color.
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the level of epithelial AR in tissue recombination experiments in which
FGF-10–expressing urogenital sinus mesenchyme cells and prostate
epithelial cells were grafted under the mouse kidney capsule [55].
In conclusion, our study provides evidence that FGF-8b is able to
induce development of mPIN lesions and very heterogeneous pros-
tate cancer with features of adenocarcinoma, carcinosarcoma, and sar-
coma in the mouse. Development of PIN lesions and other neoplastic
changes were preceded by and associated with the activation of stroma.
We propose that besides an autocrine effect on the epithelium, para-
crine activation of the stroma leading to disrupted cross talk between
epithelium and stroma is an equally important factor in FGF-8b–
induced prostate tumorigenesis (Figure 7). The results suggest that
FGF-8 commonly expressed at an increased level in human PIN lesions
and tumor tissue contributes to development and progression of pros-
tate cancer via paracrine activation of stroma.
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Figure W1. Generation and expression analysis of FGF-8b transgenic mice. (A) Genotyping PCR with primers specific for the transgene
construct resulted in a 762-bp product from DNA samples from mice positive for the transgene (lanes 3, 5, 6, 7, and 9) and no product
from WT mice (lanes 2, 4, and 8). Lane 10: negative control. (B) Analysis of FGF-8b expression by way of transgene-specific RT-PCR using
tissues of a 3-month-old TGmouse (L4). β-Actinwas used as an internal control for cDNA synthesis. DD indicates ductus deferens; Epi Cap,
epididymis caput; Epi Cau, epididymis cauda; Epi corp, epididymis corpus; Epi IS, epididymis initial segment; SV, seminal vesicles. (C)
Relative quantity of FGF-8b mRNA in VPs of WT mice and TG mice (3-5 and 12-16 months old) from different FGF-8b TG mouse lines
(L2, L3, L4, and L5) studied by qRT-PCR. mo indicates months old.
Figure W2.Weights of VP andDLPof FGF-8b–TGandWTmice in five age groups. The columns showmean±SD.One casewith a very large
carcinosarcoma tumor in the VP (weight, 3871 mg) has been excluded from the oldest (14- to 19-month-old) TG group for clarity. Statistical
significance was assessed with the Student’s t test (VP) or with the Mann-Whitney U test (DLP). ***P < .001, **P < .01, *P < .05. mo
indicates months old.
Table W1. Frequencies of Histologic Changes in Prostate in Three Age Groups.
3-6 months 7-11 months 12-21 months
WT (n = 15) TG (n = 18) WT (n = 12) TG (n = 18) WT (n = 15) TG (n = 32)
Dilatation of glands — 33 — 44 7 76
Mucinous metaplasia — 17 8 38 20 42
Epithelial hypercellularity 31 61 8 75 20 74
Epithelial hyperplasia with atypia — 11 — 38 — 53
mPIN — — — 19 — 47
Adenocarcinoma — — — — — 8
Inflammation* 13 17 25 50 13 58
Stromal hypercellularity 19 56 0 38 7 71
Stromal hypercellularity with atypia — — — 6 — 32
Sarcoma† — — — — — 16
*Includes all degrees of inflammation (score, 0-3).
†Includes carcinosarcomas.
Table W2. Predictive Ability for mPIN Lesions of Age-Adjusted Variables Studied by Logistic
Regression Analysis.
Variable P OR (CI)
Mucinous metaplasia <.001 10.93 (2.99-39.93)
Epithelial hyperplasia .012 11.07 (1.04-91.78)
Stromal hypercellularity <.001 8.60 (2.50-29.60)
Inflammation <.001 12.26 (3.02-49.84)
P values, odds ratios (OR), and 95% confidence intervals (CI) are given.
